Epiboxidine hydrochloride is a potent and selective neural nAChR agonist with K i s of 0.46 nM and 1.2 nM for rat and human α4β2 nAChRs , respectively. Epiboxidine hydrochloride is a methylisoxazole analog of the alkaloid Epibatidine, and is also an analog of another nAChR agonist, ABT 418. In Vitro Epiboxidine hydrochloride has affinity and functional at central neuronal α4β2 receptors, with K i s of 0.46 and 1.2 in rat and humen. Epiboxidine hydrochloride has activity at ganglionic-type α3β4*-nicotinic receptors of PC12 cells, with a K i of 19. Epiboxidine hydrochloride is much less toxic than Epibatidine. Epiboxidine hydrochloride stimulates sodium-22 influx in PC12 and TE671 cells, with EC 50 s of 0.18 and 2.6 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Epiboxidine hydrochloride (20 μg/kg; ip; once) treatment shows marked analgetic activity in mice . Epiboxidine hydrochloride (50 and 100 mg/kg; intraperitoneal injected; once) causes marked antinociception as measured in the hot-plate assay. Epiboxidine hydrochloride inhibits [ 3 H]nicotine binding in rat cerebral cortical membranes, with a K i of 0.6 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid